

Title (en)  
DEPSIPEPTIDES AND THEIR THERAPEUTIC USE

Title (de)  
DEPSIPEPTIDE UND IHRE THERAPEUTISCHE VERWENDUNG

Title (fr)  
DEPSIPEPTIDES ET LEUR UTILISATION THÉRAPEUTIQUE

Publication  
**EP 2089416 B1 20140226 (EN)**

Application  
**EP 07848705 A 20071123**

Priority  
• GB 2007050709 W 20071123  
• GB 0623388 A 20061123

Abstract (en)  
[origin: GB2443336A] Compounds which are Spiruchostatin analogues of the general formula (I) or (I'), isosteres thereof and pharmaceutically acceptable salts thereof may be useful in the inhibition of HDAC: <EMI ID=1.1 HE=45 WI=120 LX=420 LY=850 TI=CF> <PC>wherein R1, R2, R3 and R4 are the same or different and represent an amino acid side chain moiety and each R6 is the same or different and represents hydrogen or C1-4alkyl. These compounds can be used in pharmaceutical compositions for use in the treatment or prevention of conditions mediated by HDAC, such as cancer and inflammatory conditions, or for use in accelerating wound healing, protection of hair follicles or as an immunosuppressant. Furthermore, a process is described for selecting a compound which has an HDAC, a human cancer cell growth or an anti-inflammatory inhibitory activity. This process comprises, the synthesis of compounds of formulae (I) and (I') and screening it for activity.

IPC 8 full level  
**C07K 5/02** (2006.01); **A61K 38/06** (2006.01); **A61K 38/15** (2006.01); **A61P 9/00** (2006.01); **A61P 25/00** (2006.01); **A61P 35/00** (2006.01); **C07K 11/00** (2006.01)

CPC (source: EP GB US)  
**A61K 38/12** (2013.01 - GB); **A61K 38/15** (2013.01 - GB); **A61P 1/02** (2018.01 - EP); **A61P 3/00** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 7/00** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 13/08** (2018.01 - EP); **A61P 15/00** (2018.01 - EP); **A61P 17/02** (2018.01 - EP); **A61P 17/04** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 17/10** (2018.01 - EP); **A61P 17/14** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 31/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 5/0205** (2013.01 - EP GB US); **C07K 11/02** (2013.01 - GB); **C12P 21/02** (2013.01 - GB)

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**GB 0722996 D0 20080102**; **GB 2443336 A 20080430**; **GB 2443336 B 20101124**; AU 2007323246 A1 20080529; AU 2007323246 B2 20120419; CA 2670372 A1 20080529; CN 101589056 A 20091125; EP 2089416 A1 20090819; EP 2089416 B1 20140226; GB 0623388 D0 20070103; JP 2010510302 A 20100402; JP 5345065 B2 20131120; US 2010056434 A1 20100304; US 8247372 B2 20120821; WO 2008062232 A1 20080529

DOCDB simple family (application)  
**GB 0722996 A 20071123**; AU 2007323246 A 20071123; CA 2670372 A 20071123; CN 200780050264 A 20071123; EP 07848705 A 20071123; GB 0623388 A 20061123; GB 2007050709 W 20071123; JP 2009537705 A 20071123; US 51588007 A 20071123